Table of Content

CHAPTER 1   EXECUTIVE SUMMARY  

1.1          REPORT DESCRIPTION         

1.2          MARKET SEGMENTATION   

1.3          RESEARCH METHODOLOGY

               

CHAPTER II   DRIVERS & RESTRAINTS OF THE CHINESE PHARMACEUTICAL MARKET

 

CHAPTER III   CHINA HEALTHCARE INDICATORS VS GLOBAL HEALTHCARE INDICATORS         

3.1          DEMOGRAPHIC INDICATORS             

3.2          HEALTHCARE EXPENDITURE               

3.3          PRIVATE EQUITY / VENTURE CAPITAL INVESTMENTS      

3.4          IMPLICATIONS FROM US - CHINA TRADE WAR ON CHINA PHARMACEUTICAL MARKET         

3.4.1.      No Impact on Chinese APIs

3.4.2.      Adverse Impact on Chinese Outbound Investments, M&As

               

CHAPTER IV   CHINA PHARMACEUTICAL MARKET STRUCTURE    

4.1          HEALTHY CHINA 2020 REFORMS - REVIEW     

4.2          HEALTHY CHINA 2030 REFORMS – IMPACT ON PHARMACEUTICAL MARKET           

4.3          REGULATORY STRUCTURE  

4.3.1.      Regulatory Authorities       

4.3.2.      Current Regulatory Policies for Drugs/Pharmaceuticals             

4.3.3.      Registration Process / Approval for Domestic and Imported Drugs          

4.3.4.      Intellectual Property Rights / Patent law        

4.3.5.      Pricing and Reimbursement             

4.4          DISTRIBUTION STRUCTURE

4.4.1.      Average Sales Force Size   

4.4.2.      Bribery Penalties - Indications of Changing Pharmaceutical Distribution Practices

4.4.3.      China Hospitals Sales, 2020 - 2030 ($ bn)      

4.4.4.      China Retail Pharmacies Sales, 2020 - 2030 ($ bn)       

4.4.5.      China e-Pharmacies Sales, 2020 - 2030 ($ bn)

               

CHAPTER V CHINA PHARMACEUTICAL MARKET             

5.1          OVERVIEW            

5.2          GROWTH DRIVERS               

5.2.1.      Higher Proportion of Geriatric Population and Increased Incidence of ‘Lifestyle’ Diseases

5.2.2.      Rising Affordability             

5.2.3.      Supply-Side Reforms Augment Demand         

5.3          BARRIERS / RESTRAINTS     

5.3.1.      Non-Uniform Reimbursements        

5.3.2.      Low R&D% Investment       

5.4          COMPETITIVE LANDSCAPE

5.4.1.      Foreign Companies - Key Operating/High ROI Therapeutic Areas             

5.4.2.      Domestic Companies - Key Operating/High ROI Therapeutic Areas          

5.5          TRENDS AND FUTURE OUTLOOK       

5.5.1.      Massive in-bound funds flow to spur local R&D/innovation       

5.5.2.      Reverse brain-drain in China pharmaceutical market  

5.5.3.      Digital customer engagement becoming the necessary evil

               

CHAPTER VI CHINA PHARMACEUTICAL MARKET, BY TYPE, 2020 - 2030 ($ BN)        

6.1          CHINA SMALL MOLECULE DRUGS MARKET, 2020 – 2030 ($ BN)

6.1.1.      China Patented Small Molecule Drugs Market, 2020 – 2030 ($ bn)         

6.1.2.      China Generic Small Molecule Drugs Market, 2020 – 2030 ($ bn)           

6.2          CHINA BIOLOGICS MARKET, 2020 – 2030 ($ BN)          

6.2.1.      China Patented Biologics Market, 2020 – 2030 ($ bn)

6.2.2.      China Biosimilars Market, 2020 – 2030 ($ bn)              

6.2.3.      China Vaccines Market, 2020 – 2030 ($ bn)  

 

CHAPTER VII CHINA APIs MARKET, 2020 - 2030 ($ BN)

 

CHAPTER VIII CHINA PHARMACEUTICAL MARKET, BY KEY THERAPEUTICS, 2020 - 2030 ($ BN)             

8.1          CHINA CARDIOVASCULAR DRUGS MARKET, 2020 – 2030 ($ BN)

8.2          CHINA ANTI-INFECTIVE DRUGS MARKET, 2020 – 2030 ($ BN)     

8.3          CHINA ONCOLOGY DRUGS MARKET, 2020 – 2030 ($ BN)            

8.4          CHINA DIABETES DRUGS MARKET, 2020 – 2030 ($ BN)

               

CHAPTER IX COMPANY PROFILES     

9.1.         SINO BIOPHARMACEUTICAL LTD.     

9.1.1.      Background          

9.1.2.      Business Structure - China

9.1.3.      Products / Services - China               

9.1.4.      Distribution Network - China            

9.1.5.      Growth strategy - China     

9.1.6.      Financial Information - China            

 

9.2.         CSPC PHARMACEUTICAL GROUP LTD.             

9.2.1.      Background          

9.2.2.      Business Structure - China

9.2.3.      Products / Services - China               

9.2.4.      Distribution Network - China            

9.2.5.      Growth strategy - China     

9.2.6.      Financial Information – China

               

9.3.         ASTRAZENECA CHINA         

9.3.1.      Background          

9.3.2.      Business Structure - China

9.3.3.      Products / Services - China               

9.3.4.      Distribution Network - China            

9.3.5.      Growth strategy - China     

9.3.6.      Financial Information – China

               

9.4.         PFIZER CHINA       

9.4.1.      Background          

9.4.2.      Business Structure - China

9.4.3.      Products / Services - China

9.4.4.      Distribution Network - China            

9.4.5.      Growth strategy - China     

9.4.6.      Financial Information – China

               

9.5.         SHANGHAI PHARMACEUTICALS HOLDING COMPANY LTD.          

9.5.1.      Background          

9.5.2.      Business Structure - China

9.5.3.      Products / Services - China               

9.5.4.      Distribution Network - China            

9.5.5.      Growth strategy - China     

9.5.6.      Financial Information - China            

 

9.6.         FOSUN PHARMA

9.6.1.      Background          

9.6.2.      Business Structure - China

9.6.3.      Products / Services - China

9.6.4.      Distribution Network - China            

9.6.5.      Growth strategy - China     

9.6.6.      Financial Information - China